This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Provectus Still Won't Answer Key Questions About Skin Cancer Drug PV-10

By: Adam Feuerstein | 01/24/14 - 11:49 AM EST

Provectus Pharmaceuticals (PVCT: Pink Sheets) responded to my column about the obsolescence of its skin cancer drug PV-10 with a "letter to the editor" which was also filed as an 8-K.

Read Provectus' letter closely. It's a non-denial denial which fails to address any of the concerns and questions raised in my column. Provectus executives refuse to explain the delay in starting the phase III study of PV-10 in metastatic melanoma. As I reported, it's been two years since the company told investors that it had completed meetings with FDA and was ready to seek a Special Protocol Assessment (SPA) for the PV-10 phase III study. If PV-10 is such a promising skin-cancer drug, why has Provectus been unable or unwilling to move the drug into a phase III study, as promised?

Provectus also refuses to explain what made the latest meeting with FDA, held Dec. 18, necessary. The company claims an accelerated approval of PV-10 or Breakthrough Therapy designation is being considered. But on what substantive basis? As I reported, the only clinical study conducted with PV-10 in melanoma was completed four years ago and enrolled 80 patients. Does Provectus really expect FDA to consider this tiny study sufficient for an accelerated approval review? How so? Provectus won't say, which speaks volumes.

Let's talk about the Moffitt Cancer Center, which Provectus points to as external validation of PV-10. In its letter Friday, Provectus says this:

Also, counter to Mr. Feuerstein's claim, the Company furnished a great deal of pertinent information through its independent press agent (not spokesperson) Bill Gordon that he failed to include in his article... One announcement, issued by Moffitt Cancer Center on August 22, 2013, highlights how early clinical trials show PV-10 can boost immune response in melanoma tumors, as well as the blood stream.


The "great deal" of pertinent information sent to me by Gordon about PV-10 this week amounted to two press releases, one issued by Provectus, the other by Moffitt Cancer Center. I'm capable of looking up press releases by myself, guys, thanks for nothing. 

Provectus misleads investors about the content and significance of the Moffitt Cancer Center press release, which involved a study of PV-10 conducted in mice, not humans. The FDA doesn't approve melanoma drugs with mouse data.

Moffitt is conducting a follow-on study of PV-10 in melanoma patients, but in the year the study has been open for enrollment, Moffitt has managed to recruit only nine of a planned 15 patients, according to Moffitt study coordinator Erica Royster. I spoke with Royster on the phone earlier this morning.

This Moffitt study is designed to assess immunological and blood biomarkers of melanoma lesions injected with PV-10 and will not measure tumor response, progression-free survival or overall survival of the patients enrolled, Royster told me. Moffitt refers to the trial as a "feasibility study." In other words, Provectus will be unable to use this Moffitt study to further demonstrate the efficacy and safety of PV-10 in melanoma patients. Again, FDA doesn't base cancer drug approvals based on immunological response data, particularly from a tiny 15-patient, single center study. [That is, assuming Moffitt can actually complete the study. Enrolling only nine of 15 patients in a year isn't promising.]

By the way, I asked Royster if Moffitt was also recruiting melanoma patients for the phase III studies investigating the checkpoint inhibitors from Merck (MRK) and Bristol-Myers Squibb (BMY):

"Yes, those studies are filling up fast," she said.

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Other Posts In Adam's Biotech Beat:

Get More Investment Ideas:

Cramer: Expect Selling and Don't Buy It

08/28/14 - 12:00 PM EDT

Cramer: The Market's Real Killer

08/27/14 - 11:32 AM EDT

Dillian: Despite S&P 2000, This Is No Bubble

08/26/14 - 14:30 PM EDT

Cramer: This Is a Game of Chicken

08/26/14 - 11:34 AM EDT

Cramer: Behind Roche's InterMune Deal

08/25/14 - 11:41 AM EDT

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,062.31 -17.26 -0.10%
S&P 500 1,997.04 +0.30 0.02%
NASDAQ 4,564.4860 +6.7910 0.15%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs